Cargando…

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma. We performed comparative radioimmunotherapy (RIT) of experimental B16-F10 melanoma with novel humanized IgG to melanin h8C3 labeled wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen, Kevin J. H., Jiao, Rubin, Malo, Mackenzie E., Frank, Connor, Fisher, Darrell R., Rickles, David, Dadachova, Ekaterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680821/ https://www.ncbi.nlm.nih.gov/pubmed/31323785 http://dx.doi.org/10.3390/pharmaceutics11070348

Ejemplares similares

Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma
por: Malo, Mackenzie E., et al.
Publicado: (2020)

Beta emitters rhenium‐188 and lutetium‐177 are equally effective in radioimmunotherapy of HPV‐positive experimental cervical cancer
por: Phaeton, Rebecca, et al.
Publicado: (2015)

Targeting Melanin in Melanoma with Radionuclide Therapy
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model
por: Jiao, R., et al.
Publicado: (2020)

Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy
por: Nosanchuk, J. D., et al.
Publicado: (2018)

Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections
por: Helal, Muath, et al.
Publicado: (2020)

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer
por: Jiao, Rubin, et al.
Publicado: (2019)

A Theranostic Approach to Imaging and Treating Melanoma with (203)Pb/(212)Pb-Labeled Antibody Targeting Melanin
por: Jiao, Rubin, et al.
Publicado: (2023)

Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
por: Lindenblatt, Dennis, et al.
Publicado: (2014)

Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
por: Dadachova, Ekaterina, et al.
Publicado: (2011)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Effects of Melanized Bacteria and Soluble Melanin on the Intestinal Homeostasis and Microbiome In Vivo
por: Zhang, Yong-guo, et al.
Publicado: (2022)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models
por: Broqueza, Jaline, et al.
Publicado: (2021)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics
por: Allen, Kevin J. H., et al.
Publicado: (2018)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy
por: Cappon, Derek John, et al.
Publicado: (2023)

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report
por: Gezer, Emre, et al.
Publicado: (2019)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Radioimmunotherapy of Fungal Diseases: The Therapeutic Potential of Cytocidal Radiation Delivered by Antibody Targeting Fungal Cell Surface Antigens
por: Nosanchuk, Joshua D., et al.
Publicado: (2012)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of (177)Lutetium-labeled Radiopharmaceuticals
por: Arora, Geetanjali, et al.
Publicado: (2017)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6ccpvek2l8tushe7ru64tt438